 |
      
|
|
|
|
|
|||||
|
|
February 21, 2006
Neurochem receives fourth recommendation from Independent Safety Review Board for Alzhemed™ About Alzheimer's Disease
Alzheimer's disease (AD) is a progressive form of dementia associated with specific brain pathologies. It impairs a
person's cognitive and motor functions and gradually destroys the brain. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics to address critical unmet medical
needs. Eprodisate (Fibrillex™) is designated as an orphan drug, is a Fast Track product candidate and is also part
of FDA Continuous Marketing Application Pilot 1 and Pilot 2 programs. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA amyloidosis was concluded in April 2005. The Company has completed its
submission of a New Drug Application for Fibrillex™ that the FDA agreed in June 2005 to file and review.
Tramiprosate (Alzhemed™), for the treatment of Alzheimer's disease, is currently in Phase III clinical trials
in both North America and Europe and tramiprosate (Cerebril™), for the prevention of Hemorrhagic Stroke caused
by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial. To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
This news release contains forward-looking statements regarding tramiprosate (Alzhemed™) as well as regarding
continuing and further development efforts. These statements are based on the current analysis and expectations of
management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to
differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials
may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the endpoints
sought in the clinical trials were met (which is not certain), there is no certainty that regulators would ultimately
approve Alzhemed™ for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety,
tolerability and efficacy of our product, the expense and uncertainty of obtaining regulatory approval, including from
the FDA, and the possibility of having to conduct additional clinical trials. Further, even if regulatory approval is
obtained, therapeutic products are generally subject to: stringent on-going governmental regulation, challenges in gaining
market acceptance, and competition. Neurochem does not undertake any obligation to publicly update its forward-looking
statements, whether as a result of new information, future events, or otherwise. Please see the Annual Information Form
for further risk factors that might affect the Company and its business.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
